Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asudemotide - OncoTherapy Science/Shionogi

Next Previous
X
Search
Drug Profile

Asudemotide - OncoTherapy Science/Shionogi

Alternative Names: Asudemotide; S-288310/S-488310; S-288310/S-488410; S-488310/S-288310; S-588410

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator OncoTherapy Science
  • Developer OncoTherapy Science; Shionogi
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Oesophageal cancer
  • Phase II Bladder cancer

Most Recent Events

  • 07 Jun 2022 Efficacy and safety data from phase II trial in patients with Bladder cancer was released by the company
  • 01 Oct 2019 Pharmacodynamics data from phase I trial was released by OncoTherapy Science
  • 28 Aug 2019 No recent reports of development identified for phase-I development in Oesophageal-cancer(Neoadjuvant therapy) in Japan (SC, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top